Background Atrial fibrillation (AF) and acute myocardial infarction (AMI) share risk factors and are bidirectionally associated. Several studies found higher risks of outcomes in individuals with both ...
New York, USA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Myocardial Infarction Clinical Trial Pipeline Appears Robust With 45+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...
In the ABYSS (Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicated Myocardial Infarction on Safety and Symptomatic Cardiac Events Requiring Hospitalization) trial, interruption of ...
Interestingly, this is the same time of the day when the incidence of myocardial infarction peaks in humans. The investigators also report that this temporal-dependence in ischemia/reperfusion ...
On the other hand, they are able to protect or support neighboring cells, especially during the early phases of ischemia, which marks them as “good guys.” Thus, defining astrocyte heterogeneity in the ...
1 Nature Drug Discovery Group, School of Pharmacy, Queen’s University Belfast, Belfast, United Kingdom 2 Dermatology Department, Shanghai Zhongye Hospital, Shanghai, China Background: By far, one of ...